Pluristem Therapeutics Inc. 8-K Summary
Business Context and Reporting Period
This Form 8-K reports the results of the annual meeting of stockholders held by Pluristem Therapeutics Inc. on May 15, 2012. The filing addresses Item 5.07, Submission of Matters to a Vote of Security Holders.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance voting results.
Material Changes and Voting Results
The primary event reported is the election of directors. All eight nominees were elected to the Board of Directors. The voting breakdown for Proposal No. 1 is as follows:
| Director Name | For | Against | Abstain | Broker Non-Votes |
|---|---|---|---|---|
| Zami Aberman | 13,231,845 | 2,460,819 | 36,245 | 0 |
| Israel Ben-Yoram | 15,484,872 | 24,777 | 219,260 | 0 |
| Isaac Braun | 15,490,198 | 20,451 | 218,260 | 0 |
| Mark Germain | 15,346,513 | 164,136 | 218,260 | 0 |
| Moria Kwiat | 15,485,953 | 24,696 | 218,260 | 0 |
| Hava Meretzki | 15,493,252 | 76,104 | 159,553 | 0 |
| Nachum Rosman | 15,478,071 | 32,577 | 218,261 | 0 |
| Doron Shorrer | 15,395,837 | 114,812 | 218,260 | 0 |
Zami Aberman received a significantly lower "For" vote count compared to other directors, with a higher number of "Against" votes.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items.
Investor Verification Checklist
- Verify the total number of shares outstanding to calculate the percentage of votes cast for each director.
- Review the proxy statement for the rationale behind the higher "Against" votes for Zami Aberman.
- Confirm the terms of office for the newly elected directors.
- Check subsequent filings for any financial updates, as this 8-K contains no financial data.